Genmab's Arzerra disappoints in Phase II trial in common lymphoma
This article was originally published in Scrip
Executive Summary
Genmab's anti-CD20 monoclonal antibody drug Arzerra (ofatumumab) has resulted in a low response rate in a single-arm, single-agent Phase II trial testing it as a therapy for relapsed diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin's lymphoma (NHL). However, the company and analysts attributed the "disappointing" result to its use without chemotherapy and a heavily pre-treated population, and a Phase III trial in DLBCL is continuing.